Adempas

Land: New Zealand

Språk: engelsk

Kilde: Medsafe (Medicines Safety Authority)

Aktiv ingrediens:

Riociguat 2.5mg

Tilgjengelig fra:

Bayer New Zealand Limited

INN (International Name):

Riociguat 2.5 mg

Dosering :

2.5 mg

Legemiddelform:

Film coated tablet

Sammensetning:

Active: Riociguat 2.5mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide red Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Resept typen:

Prescription

Produsert av:

Bayer AG

Indikasjoner:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Produkt oppsummering:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Autorisasjon dato:

2014-06-25